Chromatin states define tumour-specific T cell dysfunction and reprogramming

被引:641
|
作者
Philip, Mary [1 ,3 ]
Fairchild, Lauren [2 ]
Sun, Liping [4 ]
Horste, Ellen L. [1 ]
Amara, Steven C. [1 ]
Shakiba, Mojdeh [1 ,5 ]
Scott, Andrew C. . [1 ,5 ]
Viale, Agnes [4 ]
Lauer, Peter [6 ]
Erghoub, Taha M. [5 ,7 ]
Hellmann, Matthew D. [5 ,8 ]
Wolchok, Jedd D. [5 ,7 ,9 ]
Leslie, Christina S. [2 ]
Schietinger, Andrea [1 ,5 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Computat Biol Program, New York, NY 10065 USA
[3] Weill Cornell Med Coll, Triinst Training Program Computat Biol & Med, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Ctr Mol Oncol, Integrated Genom Operat, New York, NY 10065 USA
[5] Cornell Univ, Weill Cornell Med Coll, New York, NY 10065 USA
[6] Aduro Biotech Inc, Berkeley, CA 94720 USA
[7] Mem Sloan Kettering Canc Ctr, Melanoma & Immunotherapeut Serv, New York, NY 10065 USA
[8] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY 10065 USA
[9] Mem Sloan Kettering Canc Ctr, Ludwig Ctr Canc Immunotherapy, New York, NY 10065 USA
关键词
DIFFERENTIAL EXPRESSION; TRANSCRIPTIONAL CONTROL; CANCER; EFFECTOR; LANDSCAPE; PROTEINS; BLOCKADE; ANTIGEN; BIAS;
D O I
10.1038/nature22367
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Tumour-specific CD8 T cells in solid tumours are dysfunctional, allowing tumours to progress. The epigenetic regulation of T cell dysfunction and therapeutic reprogrammability (for example, to immune checkpoint blockade) is not well understood. Here we show that T cells in mouse tumours differentiate through two discrete chromatin states: a plastic dysfunctional state from which T cells can be rescued, and a fixed dysfunctional state in which the cells are resistant to reprogramming. We identified surface markers associated with each chromatin state that distinguished reprogrammable from non-reprogrammable PD1(hi) dysfunctional T cells within heterogeneous T cell populations from tumours in mice; these surface markers were also expressed on human PD1(hi) tumour-infiltrating CD8 T cells. Our study has important implications for cancer immunotherapy as we define key transcription factors and epigenetic programs underlying T cell dysfunction and surface markers that predict therapeutic reprogrammability.
引用
收藏
页码:452 / +
页数:21
相关论文
共 50 条
  • [1] Chromatin states define tumour-specific T cell dysfunction and reprogramming
    Mary Philip
    Lauren Fairchild
    Liping Sun
    Ellen L. Horste
    Steven Camara
    Mojdeh Shakiba
    Andrew C. Scott
    Agnes Viale
    Peter Lauer
    Taha Merghoub
    Matthew D. Hellmann
    Jedd D. Wolchok
    Christina S. Leslie
    Andrea Schietinger
    Nature, 2017, 545 : 452 - 456
  • [2] TOX is a critical regulator of tumour-specific T cell differentiation
    Scott, Andrew C.
    Dundar, Friederike
    Zumbo, Paul
    Chandran, Smita S.
    Klebanoff, Christopher A.
    Shakiba, Mojdeh
    Trivedi, Prerak
    Menocal, Laura
    Appleby, Heather
    Camara, Steven
    Zamarin, Dmitriy
    Walther, Tyler
    Snyder, Alexandra
    Femia, Matthew R.
    Comen, Elizabeth A.
    Wen, Hannah Y.
    Hellmann, Matthew D.
    Anandasabapathy, Niroshana
    Liu, Yong
    Altorki, Nasser K.
    Lauer, Peter
    Levy, Olivier
    Glickman, Michael S.
    Kaye, Jonathan
    Betel, Doron
    Philip, Mary
    Schietinger, Andrea
    NATURE, 2019, 571 (7764) : 270 - +
  • [3] TOX is a critical regulator of tumour-specific T cell differentiation
    Andrew C. Scott
    Friederike Dündar
    Paul Zumbo
    Smita S. Chandran
    Christopher A. Klebanoff
    Mojdeh Shakiba
    Prerak Trivedi
    Laura Menocal
    Heather Appleby
    Steven Camara
    Dmitriy Zamarin
    Tyler Walther
    Alexandra Snyder
    Matthew R. Femia
    Elizabeth A. Comen
    Hannah Y. Wen
    Matthew D. Hellmann
    Niroshana Anandasabapathy
    Yong Liu
    Nasser K. Altorki
    Peter Lauer
    Olivier Levy
    Michael S. Glickman
    Jonathan Kaye
    Doron Betel
    Mary Philip
    Andrea Schietinger
    Nature, 2019, 571 : 270 - 274
  • [4] Studying tumour-specific T cell responses in 3D
    Minton, Kirsty
    NATURE REVIEWS IMMUNOLOGY, 2018, 18 (10) : 602 - 603
  • [5] Studying tumour-specific T cell responses in 3D
    Kirsty Minton
    Nature Reviews Immunology, 2018, 18 : 602 - 603
  • [6] Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas
    Reddy, SA
    Levy, R
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (05) : 626 - 628
  • [7] IMMUNOLOGY OF CANCER CELL - TUMOUR-SPECIFIC ANTIGENS
    HADDOW, A
    BRITISH MEDICAL BULLETIN, 1965, 21 (02) : 133 - +
  • [8] REDIRECTING ADENOVIRUS-SPECIFIC T CELLS BY A TUMOUR-SPECIFIC T CELL RECEPTOR FOR THERAPY OF HEPATOCELLULAR CARCINOMA
    Cristina, Ureche I.
    Engin, Guerlevik
    Norman, Woller
    Arnold, Kloos
    Bettina, Fleischmann-Mundt
    Michael, Manns P.
    Stefan, Kubicka
    Florian, Kuehnel
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S10 - S10
  • [9] Single-cell sequencing of tumour infiltrating T cells efficiently identifies tumour-specific T cell receptors based on the T cell activation score
    Zhang, Chaoting
    Li, Shance
    Shen, Luyan
    Teng, Xia
    Xiao, Yefei
    Yang, Wenjun
    Lu, Zheming
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (07)
  • [10] Tumour-specific microRNA expression pattern in canine intestinal T-cell-lymphomas
    Joos, Diana
    Leipig-Rudolph, Miriam
    Weber, Karin
    VETERINARY AND COMPARATIVE ONCOLOGY, 2020, 18 (04) : 502 - 508